Evidence map›Paper›PMID 38281235›Full record

ArticleMolecular biology reports2024

Co-expression of Twist and Snai1: predictor of poor prognosis and biomarker of treatment resistance in untreated prostate cancer.

Rahma Said, Javier Hernández-Losa, Teresa Moline, Rosa Somoza Lopez de Haro, Skander Zouari, Ahlem Blel, Soumaya Rammeh, Amine Derouiche, Slah Ouerhani

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Rahma SaidLaboratory of Protein Engineering and Bio-Active Molecules, National Institute of Applied Science and Technology - University of Carthage, Tunis, Tunisia. Rahma-said@hotmail.com.
Javier Hernández-LosaMolecular Biology Laboratory, Department of Pathology, Hospital Universitari Vall d'Hebron, Passeig Vall d´Hebron, 119-129, 08035, Barcelona, Spain.
Teresa MolineMolecular Biology Laboratory, Department of Pathology, Hospital Universitari Vall d'Hebron, Passeig Vall d´Hebron, 119-129, 08035, Barcelona, Spain.
Rosa Somoza Lopez de HaroMolecular Biology Laboratory, Department of Pathology, Hospital Universitari Vall d'Hebron, Passeig Vall d´Hebron, 119-129, 08035, Barcelona, Spain.
Skander ZouariUrology Department, Charles Nicolle Hospital, Tunis, Tunisia.
Ahlem BlelPathology Anatomy and Cytology Department, Charles Nicolle Hospital, Tunis, Tunisia.
Soumaya RammehPathology Anatomy and Cytology Department, Charles Nicolle Hospital, Tunis, Tunisia.
Amine DerouicheUrology Department, Charles Nicolle Hospital, Tunis, Tunisia.
Slah OuerhaniLaboratory of Protein Engineering and Bio-Active Molecules, National Institute of Applied Science and Technology - University of Carthage, Tunis, Tunisia.
Hôpital Charles-Nicolle · TNVall d'Hebron Hospital Universitari · ESNational Institute of Applied Science and Technology · TN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProstate cancer (PCa) remains one of the most complex tumors in men. The assessment of gene expression is expected to have a profound impact on cancer diagnosis, prognosis, and treatment decisions. The aim of this study was to determine the utility of the epithelial-mesenchymal transition (EMT) transcription factors Twist and Snai1 in the treatment of naïve prostate cancer. METHODS AND

resultsWe analyzed formalin-fixed paraffin-embedded (FFPE) prostate tissues from 108 PCa patients and 20 control biopsies using real-time quantitative reverse transcription-polymerase chain reaction (RT-qPCR) and 2

conclusionThese results suggest that Snai1 and Twist are overexpressed during the onset and progression of PCa malignancies and may be theranostic markers of resistance to ADT, abiraterone, or enzalutamide therapy.

Indexed as

BenzamidesNitrilesPhenylthiohydantoinProstatic NeoplasmsSnail Family Transcription FactorsTwist-Related Protein 1Androgen AntagonistsBiomarkers, TumorHumansMaleNuclear ProteinsRNA, MessengerAndrogen AntagonistsBenzamidesBiomarkers, TumorenzalutamideNitrilesNuclear ProteinsPhenylthiohydantoinRNA, MessengerSNAI1 protein, humanSnail Family Transcription FactorsTWIST1 protein, humanTwist-Related Protein 1Abiraterone and enzalutamide drugAndrogen deprivation therapyProstate cancerSnai1Taxanes drugTwist

Identifiers

PMID38281235
OpenAlexW4391298023

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.